Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1

A new study shows possible clinical benefits of intraperitoneal paclitaxel for gastric cancer. Published in the Journal of Clinical Oncology, An American Society of Clinical Oncology Journal, Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.